10-Q/A: Coeptis Therapeutics Restates Q1 2024 Financials Due to Accounting Error

Coeptis Therapeutics Holdings has filed an amended 10-Q report to reclassify notes receivable as subscription receivables after an accounting evaluation.

Summary

• Coeptis Therapeutics Holdings has restated its first quarter 2024 financials due to an error in classifying notes receivable.
• The company incorrectly recorded certain note agreements as notes receivable, which should have been classified as subscription receivables.
• This reclassification resulted in a decrease in total assets from $9,394,321 to $3,894,321 as of March 31, 2024.
• The restatement also impacted total stockholders' equity, which decreased from $4,359,365 to $(1,140,635).
• The company reported a net loss of $3,001,388 for the three months ended March 31, 2024, compared to a net loss of $7,957,833 for the same period in 2023.
• Operating expenses decreased from $6,538,951 in Q1 2023 to $2,922,383 in Q1 2024, primarily due to lower professional services expenses.
• Cash and cash equivalents decreased from $1,469,134 at the end of 2023 to $1,029,244 as of March 31, 2024.
• The company has an accumulated deficit of $90,357,648 as of March 31, 2024, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including a restatement due to accounting errors, a large accumulated deficit, and concerns about the company's ability to continue as a going concern. While there are some positive aspects, such as reduced operating expenses and a focus on innovative technologies, the overall sentiment is negative due to the company's precarious financial situation.

Positives

• The net loss for Q1 2024 was significantly lower than the net loss for Q1 2023, indicating improved financial performance.
• Operating expenses decreased substantially, primarily due to lower professional services expenses.
• The company is actively exploring strategic partnerships and focusing on innovative products and technologies.

Negatives

• The company restated its financials due to a significant accounting error, indicating a weakness in internal controls.
• The reclassification of notes receivable resulted in a substantial decrease in total assets and stockholders' equity.
• The company has a large accumulated deficit and limited cash reserves, raising concerns about its ability to continue as a going concern.
• Several notes payable are in default as of March 31, 2024.

Risks

• The company's ability to continue as a going concern is in doubt due to its accumulated deficit and limited cash reserves.
• The company's internal controls over financial reporting have been identified as ineffective.
• The company is dependent on raising additional capital through sales of equity or debt securities.
• There is no guarantee that the company will be able to achieve profitability.
• Several notes payable are in default, which could lead to further financial challenges.

Future Outlook

The company expects to continue focusing on product development, raising capital, and building infrastructure. Management does not expect the company to generate any significant revenue for at least the next two years. The company believes that the ability to raise capital through equity transactions will increase liquidity and enable the execution of management's operating strategy.

Management Comments

• Management determined the previously issued amended condensed consolidated financial statements did not give full effect to the transactions, and the notes receivable should have been recorded as subscription receivables.
• Management believes that additional financing as necessary will result in improved operations and cash flow.
• Management does not expect the Company to generate any significant revenue for at least the next two years, during which time drug development will continue toward the goal of commercializing, through a partnership or otherwise, one or more of the Company's target products or technologies.

Industry Context

The company is operating in the biopharmaceutical industry, which is characterized by high research and development costs, long development timelines, and regulatory hurdles. The company's focus on cell therapy technologies aligns with current trends in the industry, but it faces competition from other companies developing similar therapies. The company's financial challenges are not uncommon for early-stage biotech companies.

Comparison to Industry Standards

• Coeptis's financial performance is weak compared to established biopharmaceutical companies, which typically have significant revenue streams and positive cash flows.
• The company's reliance on external funding is typical for early-stage biotech companies, but its current financial position is precarious.
• The company's focus on cell therapy is in line with industry trends, but its lack of revenue and significant losses are concerning.
• Compared to companies like Kite Pharma or Juno Therapeutics, which have successfully developed and commercialized CAR T-cell therapies, Coeptis is still in the early stages of development and faces significant challenges in bringing its products to market.
• The company's co-development agreements with Vy-Gen and Deverra are similar to strategies employed by other biotech companies to share development costs and risks, but the success of these partnerships is not guaranteed.

Related Party Transactions

• In September 2023, the Company entered into a transaction with AG Bio Life Capital I LP (AG), a Delaware limited partnership, where an employee of the Company is the general partner.
• On April 17, 2024, the Company entered into an unsecured note agreement with a related party in the principal amount of $500,000 together with interest at 10%, which is due on September 30, 2024. The agreement is between the Company and an investment fund where the manager is a member of the Company's board of directors.

Stakeholder Impact

• Shareholders are negatively impacted by the restatement, the decrease in equity, and the uncertainty about the company's future.
• Employees may be concerned about the company's financial stability and its ability to continue operations.
• Customers and partners may be hesitant to engage with the company due to its financial challenges.
• Creditors face increased risk due to the company's default on several notes payable.

Next Steps

• The company will continue to focus on product development and strategic partnerships.
• The company will seek to raise additional capital through sales of equity or debt securities.
• The company will work to remediate the identified material weaknesses in its internal controls over financial reporting.

Key Dates

Keywords

restatement, financials, subscription receivable, notes receivable, accounting error, net loss, operating expenses, going concern, warrants, debt, capital raise, biopharmaceutical, cell therapy